

COVID-19: ADULT MONOCLONAL MEDICATION REQUEST FORM

Please PRINT legibly (fax #: 484-227-9028)

Ordering Provider Name:	Ce	ell phone # (required):	
Provider's email:Office Phone #:		ffice Phone #:	
Are you this patient's Primary Care Pro	vider? 🗆 Yes 🗆	No MLH Medical Staff: ☐ Yes☐ No	
If not, please provide the patient's prin	nary provider inform	nation (if they have one):	
Name	Phone #	#:	
Patient Information:			
Last Name:	First Name:	DOB:	
Cell phone #:	Email:		
Essential Worker (required): \square Yes	☐ No Occupatio	n (required):	
Address(Street):		Apt:	
City: State:	Zip (requi	red):	
	Medical Informa	ation:	
MLH MRN# (if known):			
Past Medical History:			
Life Expectancy: Individuals expected to die within one year or less (≤ 1 Year) from a chronic, end-stage			
condition prior to developing COVID-19 (required)?			
Positive COVID-19 test result (required):	_ Date: (Attach Copy of Result)	
ONSET of Covid-19 related sym	nptoms (Date)		
	Inclusion Crite	<u>ria</u> :	
Within 10 days of onset of symptoms, +PCR, non-hospitalized plus ONE of the following (1-6):			
 Age ≥ 65	BN □ Yes □ No	MI (required):	

 Immunosuppressive disease or immunosuppressive treatment	5.	Sickle cell disease
If Yes, what therapy is the patient currently receiving	6.	Pregnancy
 9. Chronic lung disease (i.e. COPD, asthma [mod-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)	7.	··
and pulmonary hypertension) □ Yes □ No 10. Neurodevelopmental disorders (i.e. cerebral palsy) or other conditions that confer medical complexity (i.e. genetic or metabolic syndromes and severe congenital anomalies) □ Yes □ No 11. Have a medical-related technological dependence (i.e. tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19]) □ Yes □ No 12. Social determinants of health which have been shown to independently negatively impact survival from COVID-19 □ Yes □ No a. If Yes, please describe □ No a. If Yes, please describe □ No be a. If Yes, please describe □ Yes □ No consider the patient meets the requirements as defined by MLH inclusion and exclusion criteria. The Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) was reviewed with the patients who is willing to undergo treatment if selected. If no test is included, you have spoken to the patient to ensure that the test will be provided to their primary provider to ensure that the Monoclonal Antibody Therapy team can obtain the test. Patients may need to be allocated monoclonal antibody therapy via weighted lottery based on patient eligibility and availability of infusion resources (for this reason, you have included all of the information requested on this form). Your submission and signature on this document indicate that, per your knowledge, the patient does not meet the exclusion criteria, listed below: a) Anticipated hospital admission due to COVID-19 b) Required oxygen therapy due to COVID-19 c) Required an increase in baseline oxygen flow rate due to COVID-19. *Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation	8.	Cardiovascular disease (including congenital heart disease) or HTN $\ \square$ Yes $\ \square$ No
complexity (i.e. genetic or metabolic syndromes and severe congenital anomalies) Yes	9.	
pressure ventilation [not related to COVID-19]) □ Yes □ No 12. Social determinants of health which have been shown to independently negatively impact survival from COVID-19 □ Yes □ No a. If Yes, please describe □ I hereby verify the following: • The patient meets the requirements as defined by MLH inclusion and exclusion criteria. • The Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) was reviewed with the patients who is willing to undergo treatment if selected. • If no test is included, you have spoken to the patient to ensure that the test will be provided to their primary provider to ensure that the Monoclonal Antibody Therapy team can obtain the test. • Patients may need to be allocated monoclonal antibody therapy via weighted lottery based on patient eligibility and availability of infusion resources (for this reason, you have included all of the information requested on this form). Your submission and signature on this document indicate that, per your knowledge, the patient does not meet the exclusion criteria, listed below: a) Anticipated hospital admission due to COVID-19 b) Required oxygen therapy due to COVID-19 c) Required oxygen therapy due to COVID-19 threatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation	10.	complexity (i.e. genetic or metabolic syndromes and severe congenital anomalies)
survival from COVID-19	11.	
 The patient meets the requirements as defined by MLH inclusion and exclusion criteria. The Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) was reviewed with the patients who is willing to undergo treatment if selected. If no test is included, you have spoken to the patient to ensure that the test will be provided to their primary provider to ensure that the Monoclonal Antibody Therapy team can obtain the test. Patients may need to be allocated monoclonal antibody therapy via weighted lottery based on patient eligibility and availability of infusion resources (for this reason, you have included all of the information requested on this form). Your submission and signature on this document indicate that, per your knowledge, the patient does not meet the exclusion criteria, listed below: Anticipated hospital admission due to COVID-19 Required oxygen therapy due to COVID-19 Required an increase in baseline oxygen flow rate due to COVID-19. *Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation 	12.	survival from COVID-19 \square Yes \square No
 The Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) was reviewed with the patients who is willing to undergo treatment if selected. If no test is included, you have spoken to the patient to ensure that the test will be provided to their primary provider to ensure that the Monoclonal Antibody Therapy team can obtain the test. Patients may need to be allocated monoclonal antibody therapy via weighted lottery based on patient eligibility and availability of infusion resources (for this reason, you have included all of the information requested on this form). Your submission and signature on this document indicate that, per your knowledge, the patient does not meet the exclusion criteria, listed below: Anticipated hospital admission due to COVID-19 Required oxygen therapy due to COVID-19 Required an increase in baseline oxygen flow rate due to COVID-19. *Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation 	I hereb	y verify the following:
patient eligibility and availability of infusion resources (for this reason, you have included all of the information requested on this form). Your submission and signature on this document indicate that, per your knowledge, the patient does not meet the exclusion criteria, listed below: a) Anticipated hospital admission due to COVID-19 b) Required oxygen therapy due to COVID-19 c) Required an increase in baseline oxygen flow rate due to COVID-19. *Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation	•	The Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) was reviewed with the patients who is willing to undergo treatment if selected. If no test is included, you have spoken to the patient to ensure that the test will be provided to their primary provider to ensure that the Monoclonal Antibody Therapy team can obtain the
 does not meet the exclusion criteria, listed below: a) Anticipated hospital admission due to COVID-19 b) Required oxygen therapy due to COVID-19 c) Required an increase in baseline oxygen flow rate due to COVID-19. *Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation 	•	patient eligibility and availability of infusion resources (for this reason, you have included all of
 b) Required oxygen therapy due to COVID-19 c) Required an increase in baseline oxygen flow rate due to COVID-19. *Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation 		
c) Required an increase in baseline oxygen flow rate due to COVID-19. *Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation	a)	Anticipated hospital admission due to COVID-19
*Treatment with monoclonal antibody therapy has not been studied in patients hospitalized due to COVID-19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation	•	
19 and may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation	c)	
COVID-19 requiring high flow oxygen or mechanical ventilation		
Cinnature of Deviden		
Signature of Provider: Date:	Signati	re of Provider: Date: